Sunday, 23 January 2022

Australia's most trusted
source of pharma news

Sunday, 23 January 2022

Off-label move a legal nightmare

Posted 23 February 2021

The TGA's recent decision to put the feelers out on the repurposing of medicines has sparked warnings it could "unravel the pharma industry in Australia" according to legal experts. 

Three options have been put forward by the TGA to encourage pharma companies, industry bodies and patient groups to seek registration of new indications but each could result in significant legal, commercial and economic consequences for industry, according to specialist law firm, Pearce IP.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.